When the App Affects the Dose: Labeling, Data, and Software
The newly released FDA Guidance “Regulatory Considerations for Prescription Drug Use – Related Software Guidance for Industry” reflects a formal convergence of labeling and prescription drug use-related software. This guidance, which was originally published in 2023 as a draft guidance, has now been finalized by FDA. Digital interactions are becoming an increasingly integral part of […]

